5-methyl-4-nitro-pyridine-2-carbaldehyde | 22279-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-methyl-4-nitro-pyridine-2-carbaldehyde
• 英文别名: 4-Nitro-5-methyl-pyridin-2-carbaldehyd；5-Methyl-4-nitropyridine-2-carbaldehyde；5-methyl-4-nitropyridine-2-carbaldehyde
• CAS: 22279-94-3
• 化学式: C₇H₆N₂O₃
• 分子量: 166.136
• InChiKey: LTMKGNODMVYSEE-UHFFFAOYSA-N

物化性质

• 熔点：
  39-40 °C(Solv: ligroine (8032-32-4))
• 沸点：
  288.7±40.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  75.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-methyl-4-nitro-pyridine-2-carbaldehyde 在 三乙烯二胺 、 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium on activated charcoal 、 氢气 、 乙酸酐 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 13.5h， 生成 7-[[2-(4-Cyanoanilino)pyrimidin-4-yl]amino]-6-methyl-indolizine-2-carbonitrile
  参考文献：
  名称：

  Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-in-dolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.074
• 作为产物：
  描述：

  2,5-二甲基吡啶 在 硫酸 、 硝酸 、 乙酸酐 、 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 41.0h， 生成 5-methyl-4-nitro-pyridine-2-carbaldehyde
  参考文献：
  名称：

  Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-in-dolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.074

文献信息

• TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
  申请人：Biswas Kaustav

  公开号：US20130157996A1

  公开（公告）日：2013-06-20

  Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  公式I的化合物可用作TRPM8的拮抗剂。这些化合物在治疗许多TRPM8介导的疾病和病症方面非常有用，并可用于制备用于治疗此类疾病和病症的药物和制剂。此类疾病的示例包括但不限于偏头痛和神经病性疼痛。公式I的化合物具有以下结构：其中变量的定义在此提供。
• US8710043B2
  申请人：——

  公开号：US8710043B2

  公开（公告）日：2014-04-29
• US9096527B2
  申请人：——

  公开号：US9096527B2

  公开（公告）日：2015-08-04
• Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase
  作者：Won-Gil Lee、Kathleen M. Frey、Ricardo Gallardo-Macias、Krasimir A. Spasov、Albert H. Chan、Karen S. Anderson、William L. Jorgensen

  DOI：10.1016/j.bmcl.2015.06.074

  日期：2015.11

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-in-dolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data. (C) 2015 Elsevier Ltd. All rights reserved.